Recently, TNF-α inhibitors has been widely used in the treatment of various inflammatory disease such as psoriasis. However, new-onset or worsening of psoriasiform eruption can be occurred paradoxically during TNF-α inhibitor treatment, that is called paradoxical effect. Here, we report a case of palmoplantar pustulosis occurred in the patient after injection of adalimumab and following golimumab for the treatment of ankylosing spondylitis. A 52-year-old man presented with asymptomatic erythematous scaly patches with pustules on his palms and soles, which developed 3 months ago. He had ankylosing spondylitis that had been treated with adalimumab for 3 years. Histopathologic examination showed psoriasiform hyperplasia with intraepidermal neutrophilic aggregation. As adalimumab is thought to be the cause of this eruption, the rheumatologist decided to discontinue adalimumab injection and his skin lesions were improved after 4 weeks treatment with cyclosporine, topical calcipotriol and corticosteroid combination cream. However, as he suffered from a relapse of back pain, golimumab as a substitute for adalimumab was initiated to control ankylosing spondylitis. After 4th injection, his palmoplantar psoriasiform eruption recurred. Considering the situation that TNF antagonist cannot be stopped, we decided to control the skin lesion with topical agent and occasional use of systemic cyclosporine and corticosteroid.